Terms: = Sarcomas AND IRF4, LSIRF, 3662, ENSG00000137265, Q15306 AND Treatment
5 results:
1. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
[TBL] [Abstract] [Full Text] [Related]
2. Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional
Park A; Oh S; Jung KL; Choi UY; Lee HR; Rosenfeld MG; Jung JU
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21618-21627. PubMed ID: 32817485
[TBL] [Abstract] [Full Text] [Related]
3. Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma.
Manzano M; Patil A; Waldrop A; Dave SS; Behdad A; Gottwein E
Nat Commun; 2018 Aug; 9(1):3263. PubMed ID: 30111820
[TBL] [Abstract] [Full Text] [Related]
4. Wnt/β-Catenin Signaling Activates Expression of the Bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types.
Vega OA; Lucero CMJ; Araya HF; Jerez S; Tapia JC; Antonelli M; Salazar-Onfray F; Las Heras F; Thaler R; Riester SM; Stein GS; van Wijnen AJ; Galindo MA
J Cell Biochem; 2017 Nov; 118(11):3662-3674. PubMed ID: 28370561
[TBL] [Abstract] [Full Text] [Related]
5. Immunomodulatory drugs target IKZF1-irf4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract] [Full Text] [Related]
